Search | Clinical Trials Finder

Conditions: Tendinopathy
Interventions: SM04755, Vehicle, White Petrolatum, Sodium lauryl sulfate; Drug · Other
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lynchburg, Virginia

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: ORT247, Placebo; Drug
Lead sponsor: Orthogonal Neuroscience Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: placebo, 0.1 mg GSK2330672, 0.3 mg GSK2330672, 1 mg GSK2330672, 3 mg GSK2330672, 10 mg GSK2330672, 30 mg GSK2330672, 60 mg GSK2330672; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Coronary Artery Bypass Graft Surgery, Atherosclerosis, Vein Occlusion
Interventions: Evolocumab, Placebo; Drug · Other
Lead sponsor: Unity Health Toronto; Other
Eligibility: 18 Years and older
Enrollment: 782 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 5
States / cities: San Francisco, California • Jacksonville, Florida • Portland, Maine + 2 more

Conditions: Safety Issues
Interventions: Placebo, NP10679; Drug
Lead sponsor: Neurop Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Distracted Driving
Interventions: Background Mode, Manual Mode, Auto-Detect Mode; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 16 Years and older
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pruritus, Atopic Dermatitis
Interventions: difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 61
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more

Conditions: Presbyopia
Interventions: AGN-241622, Vehicle; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Inglewood, California • Los Angeles, California • Mission Hills, California + 7 more

Conditions: DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma, Mediastinal Large B-cell Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Interventions: Bridging radiation therapy, Liso-cel, Post-infusion radiation; Radiation · Biological
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Dry Eye Syndrome
Interventions: TOP1630 Ophthalmic Solution, Placebo to TOP1630 Ophthalmic Solution; Drug
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Hip Fracture
Interventions: ZT-031, placebo; Drug · Other
Lead sponsor: Zelos Therapeutics; Industry
Eligibility: 30 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Dry Eye Syndromes
Interventions: IC265 Ophthalmic Solution 1%, Placebo Ophthalmic Solution (Vehicle); Drug
Lead sponsor: Iacta Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Venus Leg Ulcers
Interventions: EscharEx (EX-03), Placebo (Gel vehicle); Drug
Lead sponsor: MediWound Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Acute Adenoviral Conjunctivitis
Interventions: FST-100, FST-100 (Component #1), FST-100 Vehicle; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Acne Vulgaris
Interventions: Tazarotene Foam without irradiation, Tazarotene Foam with UVA and UVB irradiation, Tazarotene Foam with UVA, UVB, and visible light, Vehicle Foam without irradiation, Vehicle Foam with UVA and UVB irradiation, Vehicle Foam with UVA and UVB and visible light irradiation, No Treatment without irradiation, No Treatment with UVA and UVB irradiation, No Treatment with UVA and UVB and visible light irradiation; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Presbyopia
Interventions: BRIMOCHOL™ PF, Carbachol PF, Vehicle; Drug
Lead sponsor: Visus Therapeutics; Other
Eligibility: 45 Years to 80 Years
Enrollment: 629 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 42
States / cities: Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 39 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Rilvegostomig, Volrustomig, Sabestomig, AZD9592, Pembrolizumab, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab; Biological · Combination Product
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 7
States / cities: Sacramento, California • The Bronx, New York • Chapel Hill, North Carolina + 3 more

Conditions: Healthy Volunteers
Interventions: [14C]-BGB-16673; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Submental Fat
Interventions: RZL-012, Placebo; Drug
Lead sponsor: Raziel Therapeutics Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Kidney Injury
Interventions: AC607, Vehicle Only; Biological
Lead sponsor: AlloCure Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 21
States / cities: Birmingham, Alabama • San Diego, California • Stanford, California + 17 more

Conditions: Healthy Volunteers
Interventions: GLA-AF, GLA-SE, Squalene; Drug · Other
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Acne Vulgaris
Interventions: Topical Gel Vehicle, 8% NVN1000 Topical Gel, 8% NVN1000 Topical Gel and moisturizer; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Broomall, Pennsylvania

Conditions: Glaucoma and Ocular Hypertension
Interventions: Brimonidine Tartrate 0.025%, Vehicle; Drug
Lead sponsor: Eye Therapies, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Winchester, Massachusetts

Conditions: Common Cold, Pharyngitis, Fever, Congestion, Rhinorrhea, Cough, Sore-throat, Sore Throats Viral, Malaise, Headache, Runny Nose, Sneezing
Interventions: Wintergreen Throat Spray and Aspirin Tablet, Aspirin Throat Spray and Placebo Tablet, Wintergreen Throat Spray and Placebo Tablet, Placebo Throat Spray and Placebo Tablet; Drug · Dietary Supplement · Other
Lead sponsor: Applied Biological Laboratories Inc; Other
Eligibility: 18 Years to 65 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Irvine, California • Washington D.C., District of Columbia • Atlanta, Georgia + 3 more

Search by objective public record fields.

A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers

A First in Human Study of ORT247 in Healthy Volunteers

First Time in Human Study Using GSK2330672

Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery

Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers

Distracted Driving App Study for Teens and Parents/Caregivers

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

Safety and Efficacy of TOP1630 for Dry Eye Syndrome

A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women

A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants

Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers

FST-100 in the Treatment of Acute Adenoviral Conjunctivitis

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers

Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants

A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.

A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects

The Effects of GLA on Human Volunteers

A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers

Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension

Alleviation of Common Cold Symptoms